Cargando…

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline to identify potential biomarkers and to understand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arends, Rosalinda, Guo, Xiang, Baverel, Paul G., González-García, Ignacio, Xie, James, Morsli, Nassim, Yovine, Alejandro, Roskos, Lorin K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993189/ https://www.ncbi.nlm.nih.gov/pubmed/33796405 http://dx.doi.org/10.1080/2162402X.2021.1898104

Ejemplares similares

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: González‐García, Ignacio, et al.
Publicado: (2021)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
por: Baverel, Paul G., et al.
Publicado: (2018)

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
por: Zheng, Yanan, et al.
Publicado: (2018)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
por: Melillo, Giovanni, et al.
Publicado: (2021)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
por: Lee, Dae Ho, et al.
Publicado: (2023)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma
por: Huang, Xiaomin, et al.
Publicado: (2023)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Brandt, Anna, et al.
Publicado: (2023)

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma
por: Wu, Xiang, et al.
Publicado: (2021)

Biomarker driven treatment of head and neck squamous cell cancer
por: Eze, Nnamdi, et al.
Publicado: (2017)

CCTs as new biomarkers for the prognosis of head and neck squamous cancer
por: Dong, Yanbo, et al.
Publicado: (2020)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
por: Bahig, Houda, et al.
Publicado: (2019)

Circulating Tumor Cells Correlate With Prognosis in Head and Neck Squamous Cell Carcinoma
por: Zhou, Shichao, et al.
Publicado: (2021)

Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
por: Kogo, Ryunosuke, et al.
Publicado: (2022)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Exosomes: Potential Biomarkers and Functions in Head and Neck Squamous Cell Carcinoma
por: Li, Ting, et al.
Publicado: (2022)

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
por: Bonomo, Pierluigi, et al.
Publicado: (2018)

A preliminary investigation of circulating extracellular vesicles and biomarker discovery associated with treatment response in head and neck squamous cell carcinoma
por: Rodrigues-Junior, Dorival Mendes, et al.
Publicado: (2019)

Mutated TP53 in Circulating Tumor DNA as a Risk Level Biomarker in Head and Neck Squamous Cell Carcinoma Patients
por: Kampel, Liyona, et al.
Publicado: (2023)

Circulating small non coding RNA signature in head and neck squamous cell carcinoma
por: Martinez, Berta Victoria, et al.
Publicado: (2015)

Head and Neck Squamous Cell Carcinoma: NT5E Could Be a Prognostic Biomarker
por: Zhang, Yaoting, et al.
Publicado: (2022)

PES1 is a biomarker of head and neck squamous cell carcinoma and is associated with the tumor microenvironment
por: He, Yaodong, et al.
Publicado: (2023)

Identification of a Hypoxia-Related lncRNA Biomarker Signature for Head and Neck Squamous Cell Carcinoma
por: Yang, Cuifang, et al.
Publicado: (2022)

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients
por: Summerer, I, et al.
Publicado: (2015)

Microbial and inflammatory‐based salivary biomarkers of head and neck squamous cell carcinoma
por: Vesty, Anna, et al.
Publicado: (2018)

Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma
por: Alfieri, Salvatore, et al.
Publicado: (2020)

Corrigendum: Exosomes: Potential biomarkers and functions in head and neck squamous cell carcinoma
por: Li, Ting, et al.
Publicado: (2022)

Data mining on identifying diagnosis and prognosis biomarkers in head and neck squamous carcinoma
por: Ju, Guoyuan, et al.
Publicado: (2023)

Detection of Circulating Tumor Cell Subpopulations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Weller, Patrick, et al.
Publicado: (2014)

Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck
por: Harris, Ethan J., et al.
Publicado: (2020)

Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma
por: Takahashi, Hideyuki, et al.
Publicado: (2021)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

miRNAs as Biomarkers for Diagnosing and Predicting Survival of Head and Neck Squamous Cell Carcinoma Patients
por: Piotrowski, Igor, et al.
Publicado: (2021)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cf4h9oeec6igks5r650454sbli